---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-151834"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:29:18.543912+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics repurchases 4.45M shares from Apeiron at $1.58/sh, ends proxy contest

## Summary
- Company to buy 4,454,248 shares from Apeiron Parties at $1.58/share, eliminating their entire beneficial ownership.
- Apeiron withdraws its March 2023 notice to nominate three directors for the 2023 annual meeting.
- Share repurchase does not change previously disclosed cash runway into second half of 2025.
- Standstill and voting agreement applies through the earlier of 4 years or 30 days before 2027 annual meeting.
- Company plans to initiate Phase 1/2 clinical trial of lead candidate SNS-101 in mid-2023.

## SEC filing metadata
- accession: 0001193125-23-151834
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/0001193125-23-151834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/d488025d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-151834
- JSON: https://secwatch.observer/filing/0001193125-23-151834.json
- Plain text: https://secwatch.observer/filing/0001193125-23-151834.txt

## Key facts
- Material Agreements
  Sensei Biotherapeutics, Inc. entered into Purchase Agreement with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the "Apeiron Parties") (effective 2023-05-23).
  - Action: entry
  - Counterparty: Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the "Apeiron Parties")
  - Effective: 2023-05-23
  source text: On May 23, 2023, Sensei Biotherapeutics, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the “Apeiron Parties”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/0001193125-23-151834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.